NCT06493019 - Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 15, 2025

Study Completion Date

April 14, 2027

Conditions

Anal Cancer

Interventions

DRUG

Pembrolizumab

Chemoradiation Pembrolizumab 200mg IV

DRUG

Paclitaxel

Paclitaxel 50 mg/m\^2 IV

DRUG

Carboplatin

Carboplatin AUC 2 IV

RADIATION

Radiation

Delivered as per institutional standards

DRUG

Pembrolizumab

Maintenance Pembrolizumab 400mg IV

Trial Locations (4)

21201

RECRUITING

University of Maryland, Baltimore

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

53705

RECRUITING

University of Wisconsin, Madison

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

University of Wisconsin, Madison

OTHER

lead

Dustin Deming

OTHER